Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2014

View Archived Issues

Initial report on first-in-human study of 3-V Bioscience's TVB-2640

Valaciclovir approval expanded in Japan

FDA grants orphan drug status to vatiquinone for Rett syndrome

New murine models to study human hepatitis viral infection described at AASLD meeting

Transition Therapeutics reports results from ELND-005 study

Apellis to acquire Potentia Pharmaceuticals

Sanquin and Okklo collaborate to develop cyclodextrins for cardiovascular indications

Karus Therapeutics patents novel HDAC6 inhibitors

Nimbus Apollo reports new ACC2 inhibitors

SOM Biotech and Vall d'Hebron begin trial of repositioned drug for amyloidosis

New GABA(A) receptor agonists disclosed by Sichuan Haisco

MetrioPharm files IND application for immunomodulator MP-1032

A genetically attenuated P. falciparum as vaccine candidate

Cosentyx receives positive CHMP opinion for first-line treatment of psoriasis

Nintedanib obtains positive opinion in European Union for the treatment of IPF

Palovarotene receives EMA orphan medicinal product designation

In vivo protection with inactivated dengue virus antigens plus alphavirus adjuvant

EMA gives positive opinion for hepatitis C therapy Viekirax plus Exviera

Pharmacological profile of a novel PDE10A inhibitor, MT-3014

CHMP adopts positive opinion for Genzyme's Cerdelga

Studies compare time to ESRD in aHUS patients treated with supportive care or eculizumab

Kissei Pharmaceutical discloses new TRPM8 antagonists

Galapagos patents novel CFTR activators

European Commission approves Duaklir Genuair for COPD

CHMP backs Otezla for psoriasis and psoriatic arthritis

Signifor approved in E.U. to treat acromegaly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...